- Oops!Something went wrong.Please try again later.
LEXINGTON, Mass., February 10, 2022--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 2022 Global Healthcare Conference.
Dr. Brady’s conversation with Marc Goodman, Senior Research Analyst at SVB Leerink, will be available on demand beginning at 9:20 a.m. ET Wednesday, February 16, 2022. To view the webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. The event will remain archived on the website for 90 days.
About Aldeyra Therapeutics
Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005818/en/
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
Investor & Media:
Sharon Merrill Associates, Inc.